This inventor holds 1 USPTO granted patent. Top assignee: Seoul National University. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Hyeon-Jong Kim: Innovator in Monoclonal Antibody Research
Introduction
Hyeon-Jong Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. His work focuses on innovative methods for diagnosing and treating cancer.
Latest Patents
Hyeon-Jong Kim holds a patent for a specific monoclonal antibody to acetylated mouse BubR1. This patent includes a preparation method for the antibody and outlines its use in measuring the activity of cell division checkpoints based on the degree of acetylation of BubR1. The monoclonal antibody is instrumental in detecting tumor diseases, diagnosing cancer, screening anti-cancer agents, and regulating the cell division cycle.
Career Highlights
Hyeon-Jong Kim is affiliated with Seoul National University, where he conducts his research. His work has garnered attention for its potential applications in cancer treatment and diagnostics. He has demonstrated a commitment to advancing scientific knowledge and improving healthcare outcomes through his innovative research.
Collaborations
Hyeon-Jong Kim collaborates with notable colleagues, including Mi-Sun Kwon and Hyunsook Lee. Their combined expertise enhances the research efforts at Seoul National University and contributes to the development of groundbreaking medical technologies.
Conclusion
Hyeon-Jong Kim's contributions to monoclonal antibody research exemplify the impact of innovation in the medical field. His work not only advances scientific understanding but also holds promise for improving cancer diagnosis and treatment.